Timothy C. Wentworth
Known title: DirectorCIK: 0001252016
Associated companies
Transaction History
| DGX | ▲ Buy | Grant | 1,142 | $0 | 5/20/2026 | View on chart |
| DGX | ▲ Buy | Grant | 215 | $0 | 3/9/2026 | View on chart |
| DGX | ▲ Buy | Grant | 1,142 | $0 | 5/20/2026 | View on chart |
| DGX | ▲ Buy | Grant | 215 | $0 | 3/9/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus
Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.
Quest Diagnostics Preps for Q3 Earnings Amid Dividend Focus. Quest Diagnostics is approaching its third-quarter earnings report, with recent coverage highlighting its position as a dividend-paying stock. The company maintains a 2.10% dividend yield and trades at a 24.7 P/E ratio. Analysts currently set an average price target of $251.40, which sits above the current trading range.